Literature DB >> 19491821

Integration-deficient lentiviral vectors: a slow coming of age.

Klaus Wanisch1, Rafael J Yáñez-Muñoz.   

Abstract

Lentiviral vectors are very efficient at transducing dividing and quiescent cells, which makes them highly useful tools for genetic analysis and gene therapy. Traditionally this efficiency was considered dependent on provirus integration in the host cell genome; however, recent results have challenged this view. So called integration-deficient lentiviral vectors (IDLVs) can be produced through the use of integrase mutations that specifically prevent proviral integration, resulting in the generation of increased levels of circular vector episomes in transduced cells. These lentiviral episomes lack replication signals and are gradually lost by dilution in dividing cells, but are stable in quiescent cells. Compared to integrating lentivectors, IDLVs have a greatly reduced risk of causing insertional mutagenesis and a lower risk of generating replication-competent recombinants (RCRs). IDLVs can mediate transient gene expression in proliferating cells, stable expression in nondividing cells in vitro and in vivo, specific immune responses, RNA interference, homologous recombination (gene repair, knock-in, and knock-out), site-specific recombination, and transposition. IDLVs can be converted into replicating episomes, suggesting that if a clinically applicable system can be developed they would also become highly appropriate for stable transduction of proliferating tissues in therapeutic applications.

Mesh:

Substances:

Year:  2009        PMID: 19491821      PMCID: PMC2835240          DOI: 10.1038/mt.2009.122

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  145 in total

1.  A vector based on the SV40 origin of replication and chromosomal S/MARs replicates episomally in CHO cells.

Authors:  C Piechaczek; C Fetzer; A Baiker; J Bode; H J Lipps
Journal:  Nucleic Acids Res       Date:  1999-01-15       Impact factor: 16.971

2.  Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors.

Authors:  T Kafri; U Blömer; D A Peterson; F H Gage; I M Verma
Journal:  Nat Genet       Date:  1997-11       Impact factor: 38.330

3.  Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1.

Authors:  V N Kim; K Mitrophanous; S M Kingsman; A J Kingsman
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

Review 4.  Therapeutic gene targeting.

Authors:  R J Yáñez; A C Porter
Journal:  Gene Ther       Date:  1998-02       Impact factor: 5.250

5.  Mutations in the human immunodeficiency virus type 1 integrase D,D(35)E motif do not eliminate provirus formation.

Authors:  M Gaur; A D Leavitt
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

6.  Development of a self-inactivating lentivirus vector.

Authors:  H Miyoshi; U Blömer; M Takahashi; F H Gage; I M Verma
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

7.  Specific and independent recognition of U3 and U5 att sites by human immunodeficiency virus type 1 integrase in vivo.

Authors:  T Masuda; M J Kuroda; S Harada
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

8.  A third-generation lentivirus vector with a conditional packaging system.

Authors:  T Dull; R Zufferey; M Kelly; R J Mandel; M Nguyen; D Trono; L Naldini
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

9.  Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery.

Authors:  R Zufferey; T Dull; R J Mandel; A Bukovsky; D Quiroz; L Naldini; D Trono
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

Review 10.  HIV-1: fifteen proteins and an RNA.

Authors:  A D Frankel; J A Young
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

View more
  90 in total

Review 1.  Zinc-finger nucleases for somatic gene therapy: the next frontier.

Authors:  Shamim H Rahman; Morgan L Maeder; J Keith Joung; Toni Cathomen
Journal:  Hum Gene Ther       Date:  2011-07-22       Impact factor: 5.695

Review 2.  Hybrid lentiviral vectors.

Authors:  Waseem Qasim; Conrad A Vink; Adrian J Thrasher
Journal:  Mol Ther       Date:  2010-04-20       Impact factor: 11.454

3.  Nonintegrating foamy virus vectors.

Authors:  David R Deyle; Yi Li; Erik M Olson; David W Russell
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

Review 4.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

5.  Respiratory syncytial virus engineered to express the cystic fibrosis transmembrane conductance regulator corrects the bioelectric phenotype of human cystic fibrosis airway epithelium in vitro.

Authors:  Anna R Kwilas; Mark A Yednak; Liqun Zhang; Rachael Liesman; Peter L Collins; Raymond J Pickles; Mark E Peeples
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

Review 6.  Viral vector-based tools advance knowledge of basal ganglia anatomy and physiology.

Authors:  Rachel J Sizemore; Sonja Seeger-Armbruster; Stephanie M Hughes; Louise C Parr-Brownlie
Journal:  J Neurophysiol       Date:  2016-02-17       Impact factor: 2.714

7.  Adenoviral vector DNA for accurate genome editing with engineered nucleases.

Authors:  Maarten Holkers; Ignazio Maggio; Sara F D Henriques; Josephine M Janssen; Toni Cathomen; Manuel A F V Gonçalves
Journal:  Nat Methods       Date:  2014-08-24       Impact factor: 28.547

Review 8.  Targeted gene therapies: tools, applications, optimization.

Authors:  Olivier Humbert; Luther Davis; Nancy Maizels
Journal:  Crit Rev Biochem Mol Biol       Date:  2012 May-Jun       Impact factor: 8.250

9.  Activation of EphA receptors mediates the recruitment of the adaptor protein Slap, contributing to the downregulation of N-methyl-D-aspartate receptors.

Authors:  Sophia Semerdjieva; Hayder H Abdul-Razak; Sharifah S Salim; Rafael J Yáñez-Muñoz; Philip E Chen; Victor Tarabykin; Pavlos Alifragis
Journal:  Mol Cell Biol       Date:  2013-02-04       Impact factor: 4.272

Review 10.  Therapeutic potential of combined viral transduction and CRISPR/Cas9 gene editing in treating neurodegenerative diseases.

Authors:  Joshua Kuruvilla; Andrew Octavian Sasmita; Anna Pick Kiong Ling
Journal:  Neurol Sci       Date:  2018-08-03       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.